Dutch diagnostics firm Qiagen claims to have taken a leading position in the personalised healthcare market after purchasing companion diagnostics expert DxS in a deal worth up to $130m. The acquisition provides Qiagen with a portfolio of seven molecular diagnostic assays that allow ...
Please Login to read the full article.
